Triclabendazole Market: Business Overview and Global Development Trends

Triclabendazole Market: Introduction

Triclabendazole was first used to treat Fasciola hepatica infections in animals in the early 1980s. It has established itself as the primary anti-fluke medication on the market due to its strong action against immature flukes. Triclobendazole has recently been used to treat human cases of fascioliasis; and currently, it is the treatment of choice for this infection as well.

Read Report Overview –

https://www.transparencymarketresearch.com/triclabendazole-market.html

Triclabendazole became a generic drug because patents in many countries expired in the late 1990s. During that time, a lot of products were created. In the early 2000s, Agrovet Market Animal Health introduced Trivantel 15, a 15% triclabendazole suspension. Agrovet Market Animal Health also developed and launched the first triclabendazole injectable solution (in combination with ivermectin) in 2009. Fasiject Plus, a 36% triclabendazole and 0.6% ivermectin solution; is utilized to treat Fasciola hepatica (both immature and adult liver flukes), roundworms, and ectoparasite infections.

Key Drivers, Restrains, and Opportunities of Global Triclabendazole Market

Increase in prevalence of fascioliasis is driving the triclabendazole market. Fascioliasis is a foodborne trematode infection with a worldwide distribution. Fasciola infection has been reported in 81 countries, and is considered a neglected zoonotic disease by the World Health Organization. Two accepted species, Fasciola hepatica and Fasciola gigantica, infect a wide range of mammals including livestock and humans. It was estimated that between 2.6 million people were infected around the world with Fascioliasis. Given the emerging character of fascioliasis and reports of its expanding endemic areas, it is likely that the number of infections around the world surpasses previous estimates.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82892

Fascioliasis is found in focal areas of more than 70 countries, in all continents except Antarctica. It is found in parts of Latin America, the Caribbean, Europe, the Middle East, Africa, Asia, and Oceania. Fasciola gigantica is found in fewer geographic regions. Human cases have been reported in the tropics, in parts of Africa and Asia, and also in Hawaii. Triclabendazole is indicated for the treatment of fascioliasis in patients aged 6 years old and above, which drives its market.

Governments of developing countries are making significant investments to modernize healthcare infrastructure, which is likely to increase access to health care. This is expected to increase the demand for Triclabendazole. Increase in prevalence of Fascioliasis in developing countries presents lucrative opportunities for the global Triclabendazole market.

Request for Custom Research –

https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=82892

North America to Capture Major Share of Global Triclabendazole Market

North America is expected to account for major share of the global Triclabendazole market due to high prevalence of Fascioliasis among the population. Moreover, well-established healthcare infrastructure and hub for key industry players are major factors boosting the Triclabendazole market in the region.

The Triclabendazole market in Asia Pacific is estimated to expand at a rapid pace during the forecast period owing to expansion of health care infrastructure. Moreover, surge in Fascioliasis infection is likely propel the market in the region.

Key Players Operating in Global Triclabendazole Market

The global Triclabendazole market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Demand for products to treat Fascioliasis has increased in emerging as well as developed markets. Growth strategies adopted by leading players are likely to drive the global Triclabendazole market.

Pre Book Triclabendazole Market Report at

https://www.transparencymarketresearch.com/checkout.php?rep_id=82892&ltype=S

Major players operating in the global Triclabendazole market are listed below:

  • Alivira Animal Health
  • Hangzhou Think Chemical
  • Hebei Veyong Animal Pharmaceutical
  • Hengdian Group Holding
  • Ipca Laboratories
  • Jiangsu Quality Horizons Pharmtech
  • Lasa Laboratory
  • Novartis pharmaceuticals
  • Procyon Life Science
  • Rakshit Drugs Private

More Trending Reports by Transparency Market Research –

Diagnostic Imaging Services Market:

https://www.prnewswire.com/news-releases/increasing-adoption-of-new-technology-to-help-diagnostic-imaging-services-market-reach-valuation-worth-us465-bn-by-2027-transparency-market-research-301008184.html

Digital Dose Inhalers Market:

https://www.prnewswire.com/news-releases/global-digital-dose-inhalers-market-to-reach-a-value-of-us-4-3-bn-by-2027–growing-at-a-cagr-of-10-from-2019-to-2027-transparency-market-research-300999357.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Comments are closed